Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
382 Results for "
driven
" in MedChemExpress (MCE) Product Catalog:
Products (382)
382 Results for "driven" in MCE Product Catalog:
Cat. No.: HY-169153
CAS No.: 1984784-12-4
Target:
Research Areas:
Cot inhibitor-3 (Compound 33) is a potent and selective cancer osaka thyroid (COT) kinase inhibitor, with an IC50 of 4 nM. Cot inhibitor-3 can be used to prevent inflammation-driven lameness .
Cat. No.: HY-174993
CAS No.: 2493156-15-1
FHND5071 (1H) is a selective inhibitor targeting the RET (rearrangement during transfection) tyrosine kinase. FHND5071 (1H) is promising for research of RET-driven cancers (such as thyroid cancer, lung cancer, etc.) .
Cat. No.: HY-P2471
Target:
Research Areas:
Cat. No.: HY-164513
CAS No.: 2540915-70-4
Target:
Research Areas:
NHTD is a KRAS-PDEδ inhibitor. NHTD targets the prenyl-binding pocket of PDEδ, altering the cellular localization of KRAS, thereby inhibiting the proliferation of KRAS-mutant cancer cells and inducing apoptosis. NHTD can be used for research on KRAS-driven non-small cell lung cancer (NSCLC) .
Cat. No.: HY-120663
CAS No.: 1884321-89-4
Target:
Research Areas:
KRCA-0713 is an ALK inhibitor with anti-ALK activity. KRCA-0713 showed promising anti-ALK activity in enzyme and cell-based experiments. KRCA-0713 was shown to effectively inhibit ALK-driven tumor growth in H3122 xenograft model studies, similar to the effect of ceritinib .
Cat. No.: HY-144110
CAS No.: 2425804-98-2
HCV-IN-37 (Compound 3d) is a potent inhibitor of HCV. HCV-IN-37 is orally available and long-lasting in rat plasma after oral administration to rats by a single dose of 15 mg/kg. The high potency of active derivative HCV-IN-37 is primarily driven by the inhibitory effect on the virus entry stage .
Cat. No.: HY-174841
CAS No.: 2229835-58-7
EGFR/HER2-IN-19 (Compound L1) is a dual inhibitor against epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). EGFR/HER2-IN-19 is promising for research of cancers driven by EGFR/HER2 .
Cat. No.: HY-186283
CAS No.: 2719667-13-5
GNE-0749 is an orally active pan-RAF inhibitor with a Ki value of 0.061 nM against CRAF. GNE-0749 inhibits RAF dimer signaling via a DFG-out/αC-helix-in binding mode, prevents paradoxical activation of the MAPK pathway, and suppresses downstream MEK/ERK/RSK signal transduction. GNE-0749 can be used in studies related to KRAS G12C mutation-driven cancers .
Cat. No.: HY-189204
CAS No.: 3110002-64-4
FGFR2-IN-4 is a selective, orally active FGFR2 inhibitor, with IC50 values of 10.0 nM and 5.8 nM against wild-type FGFR2 and the FGFR2 V565F mutant, respectively. FGFR2-IN-4 induces necroptosis in FGFR2-driven tumor cells. FGFR2-IN-4 induces tumor regression in xenograft models harboring FGFR2 inhibitor-resistant mutations without altering serum phosphate levels. FGFR2-IN-4 is used to investigate FGFR2-driven malignancies, including intrahepatic cholangiocarcinoma and gastric cancer .
Cat. No.: HY-187863
CAS No.: 2991354-62-0
Debecarasib is a KRAS inhibitor. Debecarasib exhibits antitumor activity and can be used in research on KRAS mutation-driven cancers.
Cat. No.: HY-179538
Target:
Research Areas:
CSH-4044 can be isolated from fermented wheat germ extract. CSH-4044 is a unique benzothiazole compound. CSH-4044 can inhibit PIM3-driven BAD phosphorylation in pancreatic cancer cell lines as well as reducing DYRK1A-induced Tau phosphorylation in neuronal cells .
Cat. No.: HY-180794
LHQ766 is a highly selective, orally active, covalent FGFR2 inhibitor with an IC50 of 7.3 nM. LHQ766 significantly suppresses phosphorylation of FGFR2 and its downstream signaling molecules FRS2-a, Akt and ERK1/2. LHQ766 selectively suppresses the proliferation of FGFR2-driven cancer cells .
Cat. No.: HY-177895
CAS No.: 3031413-24-5
IAM1363 is a selective, irreversible, and blood-brain barrier-permeable HER2 inhibitor . IAM1363 targets wild-type HER2 and oncogenic HER2 mutants (including exon 20 mutations), with no off-target EGFR inhibitory activity. IAM1363 can be used to study HER2-driven solid tumors, including colorectal cancer, non-small cell lung cancer, bladder cancer, and breast cancer .
Cat. No.: HY-179648
CAS No.: 1240857-57-1
Target:
Research Areas:
CD28-IN-2 is a selective CD28-B7 interaction (IC50: 22.4 μM) inhibitor that binds directly to CD28, with a Kd value of 24.1 μM. CD28-IN-2 inhibits CD28-driven immune activation and blocks T cell costimulation. CD28-IN-2 can be used for the study of antitumor immunity and immune-related disorders .
Cat. No.: HY-113917
CAS No.: 1002351-34-9
Target:
Research Areas:
JNJ 40279486 is a novel and highly selective histamine H4 receptor antagonist with a Ki of 9 nM. JNJ 40279486 can be used in the research of immune-driven inflammatory diseases .
Cat. No.: HY-E70608
Target:
Research Areas:
PcrA spirase is an ATP-driven 3′ to 5′ helicase responsible for unwinding double-stranded DNA (dsDNA). PcrA spirase binds to dsDNA and unwinds it into two single-stranded DNAs (ssDNA).
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
